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 Coronary arteries disease (CAD) is a leading cause of death in United States and rest of 
the world. It mostly involves atherogenic formation within the walls of the coronary arteries, 
which in turn restricts the adequate perfusion to the heart muscle. This leads to myocardial 
infarction and sudden death. In the past few decades the theories of coronary arteries disease 
pathogenesis have changed. The facts reveal that the onset of the disease can develop as early as 
childhood. The degree of the disease gradually progresses in stages and it is regarded as a 
complex, ongoing inflammatory process that begins with initial endothelial dysfunction. There 
are multiple risk factors that directly and indirectly impacts the development and progression of 
CAD such as hypercholesterolemia, smoking, hypertension, diabetes, stress , high fat meals, lack 
of exercise, alcohol abuse, obesity and recently chronic infections were added to the list as well. 
Moreover, we realize now that coronary artery disease runs in the family and there are some risk 
factors that can not be altered or controlled such as age, sex and heredity. We know that the first-
degree relatives of people who suffers from coronary artery disease at the early age are at much 
greater risk that others. Coronary artery disease is considered to be highly complex 
heterogeneous disease that results from blended effect of multiple genes. In recent years, 
researchers have identified the involvement of about 400 genes that might contribute to or to 
protect against development of disease.(Dzau and Liew 2007). Although, the definite 
conformation that even half of those is actually involved is still a long way from determination. 
The bigger question arises from all this information. Can we take an individual genomic profile 
and translate it into something that’s clinically useful? Rather, than discuss all 400 genes that 
have been implicated, this paper will focus on several of the best-understood genes in order to 
find their practical application. Among them are disease-causing genes, susceptibility genes and 
disease-linked genes. It is important to keep in mind that this situation is rapidly changing and 
hopefully in future genetic approaches will shape the practice of medicine in fundamental ways.  
Normal structure and physiology 
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The heart functions as a pump that delivers blood to the rest of the body. It consists of the 
three main layers: endocardium, myocardium and epicardium which surrounds by pericardium. 
Just like all other organs it has its own blood supply which delivered via two coronary arteries 
that branches of the aorta. The right coronary artery (RCA) lies in the coronary sulcus and 
supplies blood to the right ventricle, right 
atrium, and some portion of posterior wall of the 
left ventricle as well as sinoatrial (SA) and 
atrioventricular (AV) node. The left coronary artery 
(LCA) immediately branches into the left 
anterior descending artery (LAD) and the 
circumflex artery (Cx). The LAD primarily 
supplies blood to the wall of the left ventricle and 
ventricular septum as well as to the anterior wall 
of the right ventricle. The Cx encircles the heart and 
lies in the anterior interventricular sulcus and 
supplies blood to left atrium, lateral wall of the left 
ventricle and partially supplies SA node and posterior wall of the left ventricle (Fig 1). Delivery 
of blood to myocardium is complicated by compression of intramyocardial vessels during 
systole, which results in the retrograde blood flow in coronary arteries during diastole. Therefore, 
subendocardial layer of the myocardium is more susceptible to hypoperfusion because 
ventricular diastolic pressure opposes the driving pressure for flow. Development of CAD will 
further complicate myocardial perfusion. 
 Coronary arteries consist of three layers: the innermost tunica intima, tunica 
media, and the outermost  tunica adventitia. The tunica intima forms an inner lining of a artery 
and is in direct contact with blood. It is comprised of single layer of squamous epithelial cells, 
called endothelium that is embedded in an 
extracellular matrix. The internal elastic lamina 
separates the tunica intima from the tunica media (Fig 2 
).  
 
Endothelial cells secret locally acting chemical mediators that influence the contractile state of 
the overlying smooth muscle that play a major role in the control of the vascular tone. These 
molecules include vasodilators such as prostacyclin, endothelial-derived relaxing and 
hyperpolarizing factors (EDRF), (EDHF). It also produces vasoconstrictor substances, such as 
endothelin and prostanoids. In addition, endothelial cells synthesize and secrete heparans and 
growth factor that regulates smooth muscle cell proliferation. Endothelium remains healthy by 
secreting different substances that prevent it from platelets aggregation or adhesion of other 




Figure 1. cross-sectional view of 






elastic fibers. It’s primary role to control the diameter of the lumen by smooth muscle cell 
contraction or relaxation. Tunica externa is the most outer layer and consists of elastic and 
collagen fibers. It contains numerous nerve ending and tiny vessels that supply tissue of the cell 
wall itself as well as connects the artery to the surrounding tissue. This layer separates from 
media by network of elastic fibers, called external elastic lamina. 
 
Pathophysiology of CAD Atherosclerosis is the major cause of CAD. Theories of the 
pathophysiology of atherosclerosis underwent big changes over time. Few decades ago it was 
looked as mostly disorder of lipid storage, and later it was considered to be disorder of lipid 
metabolism. Further, CAD was looked as disease of the smooth muscle proliferation. With the 
discovery of inflammatory cells and molecule in plaques led to conclusion that disease might be 
inflammatory in nature. Current views on pathogenesis of atherosclerosis are as follows. The 
development of an atherosclerotic plaque is a multi step process. The presence of risk factors for 
CAD, such as hypercholesterolemia, cigarette smoking, hypertention, diabetes mellitus and shear 
stress are associated with endothelial dysfunction. These conditions gradually damage healthy 
and smooth lining of endothelium. This is the first step in development of atherosclerosis and it 
results in increased permeability of endothelium (fig 3). 
 
 
 Once the layer is damaged, the excess low density lipoproteins and other cellular waste product 
can easily get into the inner layer of an artery wall. While entrapped low density lipoprotein is 
progressively accumulates and undergo oxidation. This initiates inflammatory response and 
stimulates smooth muscle cells proliferation. In response to invasion, endothelium and smooth 
muscle cells release mediators to initiate recruitment of leukocytes, T-cells and monocytes into 
the developing lesion. Furthermore, intralesional monocytes become macrophages. They eat and 
digest large amounts of surrounding oxidized low density lipoprotein. As of the result of this 
process, these lipid filled macrophages are becoming foam cells, due to their foamy appearance. 
Together with T cells and monocytes, they form the bulk of “fatty streaks”. ”. The next stage in 
development of atherosclerosis is a formation of “intermediate or fibrofatty lesion” which is 
more complex in composition. The combination of fatty streaks growth and ongoing 
inflammation, stimulate smooth muscle cells to multiply and migrate to an injury site. As these 
cells become noncontractile and fibrous they migrate to the top of the atherosclerotic plaque, 
forming a cap over it. These lesions might not be immediately harmful and may be viewed as 









harder and looses its elasticity. Calcium ions binding to the site of the plaque formation might 
contribute to lack of elasticity as well. As plaque expands into the lumen of a coronary artery, 
blood flow is greatly reduced through that artery. At this stage physical symptoms such as chest 
pains and shortness of breath may occur which associates with angina pectoris. However, it is the 
physical disruption of the plaque exhibits an acute coronary event such as myocardial infarction. 
The rupture of the plaque usually occurs due to increased pressure in a narrow artery. It might 
cause the complete occlusion due to blood clot formation cascade and manifest MI or sudden 
death.  
Genomic approach to CAD 
The biggest challenge for scientists of a new era of genetics is to identify the genes and 
gene expression changes that are responsible for pathological process of CAD. Two main 
projects: human genome project and international hapmap project provided a crucial data for 
genetic analysis in a complex heterogenic disease such as atherosclerosis and coronary artery 
disease. To study such as complex diseases, scientists recently have been using two general 
categories of study designs such as association studies and linkage studies. In Linkage studies, 
the goal is to identify the inheritance of the disease in large families throughout few generations. 
It is possible if we are able to identify single nucleotide polymorphism (SNP) on the fragment of 
the chromosome that is inherited by family who is affected by a disease but not those who is 
disease free. Furthermore in this design, we concentrate on identifying the gene variation of our 
interest after narrowing down the section of a chromosome. This methodology is found to be 
helpful especially in identifying diseased genes that inherited in a Mendelian fashion. Gene 
disease associated study was introduced in 1996. It is designed to identify genetic variation of 
available genome in associations with specific trait or disease of interest. Two independent 
groups are usually participate in these studies.  Those groups are, “cases” which are those 
individuals who has been diagnosed with a disease and “control” are those who are similar 
people within same parameters that are disease free. After carefully calculated results, if 
frequencies of genetic variation are greater in individuals who are affected by a disease then it 
said to be associated with a disease. Positive association cannot be interpreted as causation, but 
only statistical association for the most part. Both of these methods have their advantages and 
disadvantages just like any other studies.  
Throughout years of genetic study, molecular biologists have identified several disease-
causing genes for disorders in lipid metabolism. They are directly related to development of 
coronary artery disease. In order to understand dyslipidemia disorders, it’s important to 
understand the physiology of lipid metabolism. Lipids are hydrophobic and therefore have to be 
transported by lipoproteins in blood. Different lipoproteins have variety of integrated and 
peripheral apoproteins that perform a different functions such as structural integrity, receptor 
binding, and enzyme activation. Lipoproteins are categorized by their density of protein content. 
They divide into two major groups high density lipoproteins (HDL) and non-high density 
lipoproteins. Non-high density lipoproteins are further subdivided into chylomicrons, very-low 
density lipoprotein, intermediate density lipoproteins and low-density lipoproteins. They 
transport lipids from sites of absorption or synthesis to sites of their utilization. High-density 
lipoproteins are considered as “good cholesterol”. They are responsible for transport of excess 
lipids in circulation back to the liver.    
For  example Apoprotein B mostly found on non-high density lipoprotein and  involves 
in assembly and packaging of ingested triglycerides and cholesterol  into non-high density 
lipoproteins. Apoprotein E involves in receptor binding to hepatocytes via (LDL receptor). 
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Through this mechanism, liver uptakes the necessary lipid contents from non-high density 
lipoprotein. Apoprotein C binds to adipocytes and skeletal muscle cell via lipoprotein lipase, 
which acts as the receptor to facilitate lipid absorption.  
Disease-causing genes have been identified for disorders in lipid metabolism such as 
familial hypercholesterolemia, familial defective Apolipoprotein B, Apolipoprotein A 
deficiency, Tangier disease, Autosomal recessive hypercholesterolemia, Sitosterolemia ect.                                                                                  
Familial hypercholesterolemia (LDL)receptor 
Familial hypercholesterolemia is an autosomal dominant disease defined by the presence 
of mutation in the low-density lipoprotein receptor gene. It characterized by severely elevated 
plasma level of low density lipoprotein (Saint-Jore B et al., 2000) Heterozygouse familial 
hypercholesterolemia is the most prevalent and affect about 1 in 500 people. Affected 
heterozygous individual exhibit plasma cholesterol levels in the range of 300-400 mg/dl. 
Clinically, patients develop severe atherosclerosis involving multiple vascular territories but 
especially in coronary arteries. This leads to premature coronary atherosclerosis in fourth decade 
of life and often requiring bypass surgery early in life. Familial hypercholesterolemia patients 
were found to have one copy of mutated low density lipoprotein gene, which normally is located 
on chromosome 19p13. A variety of point, deletion and splice mutation have been described. 
Effect of this mutation leads to loss of its function. The mutant low density lipoprotein receptor 
has reduced affinity for removal of apolipoprotein B and E from the circulation. (Marian 
Ali,2000) Because Familial hypercholesterolemia is not only relatively common and associated 
with a high risk of early coronary artery disease but is treatable with LDL-C-lowering strategies, 
this genetic disorder meets the World Health Organization criteria for systematic screening. It 
has been estimated that familial hypercholesterolemia is properly diagnosed in only 15% of 
affected Canadians and as many as 30% of the patients do not survive their first myocardial 
infarction. Therefore, early detection of the disease has the potential to save life and prevent 
morbidities (Yuan et al.,2006) 
Apolipoproteins are important components of lipoprotein particles. Current data shows 
that measurements of various apoliportroteins may help to predict the risks of coronary artery 
disease ( Walldius & Jungner, 2004).Their involvement in synthesis and metabolism of 
lipoproteins are gradually being defined. In addition to stabilizing lipoprotein structure, some of 
lipoproteins act as ligands to tissue receptors, while others activate or inhibit enzymes involved 
in metabolic steps in circulation or tissues. 
Apolipoprotein A  deficiency. 
Apolipoprotein A has two major forms A1 and A2. Apolipoprotein A1 is associated with high 
density lipoprotein cholesterol, and may be largely responsible for determining the plasma level 
of it. In addition apolipoprotein A1is the ligand for ATP-binding cassette protein and hence is 
involved in the docking procedure by which excess cholesterol in peripheral cells is externalized 
to high density liporprotein (Walldus & Jungner,2004). Its been reported that deficiency of 
apolipoprotein A1and low levels of high density liporprotein cholesterol were significantly 
related to an increased risk of cardiac mortality in patients with coronary artery disease(Walldus 
& Jungner,2004). Gene coding for apolipoprotein A1is located on the long arm of chromosome 
11. Two polymorphism of apolipoprotein A1gene namely G to A substitution at -75bp of 
transcription start site and C to T substitution at +83 bp have been implicated in susceptibility to 
coronary artery disease and shown to influence plasma lipid levels (Taranjit et al.,2008) Many 
studies are controversial about the effect of particular gene polymorphism on pathogenesis of 
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atherosclerosis and coronary artery disease, but in combination with other polymorphic variants 
may be better predictor of disease risk in future. 
Familial Defective Apolipoprotein B 
Plasma lipoproteins are important determinants of atherosclerosis. Apolipoprotein B is a 
large amphipathic glycoprotein that exists in two forms and plays an important role in lipid 
metabolism. Both forms are produced by the same apolipoprotein gene: apolipoprotein b-48, 
which is required for chylomicron production in the small intestine and apolipoprotein; b-100, 
which is required for very low density lipoprotein production in the liver. In addition, 
apolipoprotein b-100 is the ligand for low density lipoprotein-receptor-mediated endocytosis of 
low density lipoprotein particles.(Whilfield et al.,2004)  Mutation in apolipoprotein b-100 is 
characterized by increased plasma low density lipoproteins and very low density lipoprotein 
levels and has clinical features of hypercholesterolemia  and premature coronary artery 
disease(Marian.Ali.2000). Familial defective apolipoprotein b-100 is a second relatively 
common cause of severe autosomal dominant hypercholesterolemia (Dzau. 2007). It is relatively 
common, with estimated frequency of 1 out of 500 in normal population and clinically not 
possible to distinguished from heterozygous familial hypercholesterolemia (Whilfield et 
al.,2004).  The most common mutation is R3500Q which involves in substitution of a glutamine 
for arginine at the position 3500 (Whilfield et al.,2004). Other point mutation, R3500W and 
R3500C are rare cause of familial defective apolipoprotein b-100 (Real et al.,2003). Low density 
lipoproteins of affected individual will have a 90% decrease in affinity for low density 
lipoprotein receptor and low density lipoproteins clearance will be markedly impaired. Therefore 
routine screening is feasible and should be performed not only in subjects with clinical 
phenotypes but also in asymptomatic subjects with elevated  low density lipoprotein 
levels.[Ali.2000] Treatment is similar to that of familial hypercholesterolemia with reliance on 
statin therapy, which  both decrease very low density lipoprotein production and enhances 
clearance of very low density lipoprotein remnants[Dzau.2007] 
Other mutations of Apolipoprotein b-100  may cause familial hypobetalipoprotenimia, 
which is characterized by hypocholesterolemia and resistance to atherosclerosis and coronary 
artery disease (Whitfield et al 2004). 
Autosomal recessive hypercholesterolemia is caused by  mutation in a putative adaptor 
receptor protein called ARH, that function in the internalization of low density lipoprotein 
receptor and cargo. This recessive disorder is characterized by severe hypercholesterolemia, 
xanthomatosis and premature coronary artery disease (Arca et al., 2002). Autosomal recessive 
hypercholesterolemia did not associated with the low density lipoprotein receptor or 
apoliporpotein b genes and exhibited an autosomal recessive inheritance, with the parents of the 
affected subjects having normal low density lipoprotein cholesterol values [Dzau.2007]. 
Interestingly, the function of low density lipoprotein receptor is near to normal in their cultured 
fibroblast but is impaired in lymphocytes, macrophages and hepatocytes. Low density 
lipoprotein receptor protein is present in these cells within normal limits but dispersed unevenly 
with most of the receptor residing on the plasma membrane, where it binds to low density 
lipoprotein but fails to internalize and degrade its cargo [Dzau.2007]. This specific disorder is 
rare and prevalent in Sardinia, Italy. Two ARH mutation were present in all 17 unrelated 
Sardinians families with ARH: a frameshift mutation (C432insA) in exon 4( ARH1) and 
nonsense mutation (C65G->A) in exon 1(ARH2) (Arca et al., 2002) . Screening of the coding 
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regions of ARH with similar phenotype in other random parts of the world revealed that only 
four out of 40 of them were positive for ARH1 mutation and all happened to be Italian. 
Low circulating serum levels of high density lipoprotein cholesterol seem to be a frequent 
lipoprotein disorder in coronary artery disease and can be caused by either genetic or lifestyle 
factors. Many gene abnormalities can cause this lipid disorder. 
Tangier disease is a rare disorder of lipid metabolism, characterized by extremely low 
levels of high density lipoprotein cholesterol. It is caused by mutation in the adenosine 
triphosphate-binding cassette transporter A1 (ABCA 1), also known as the cholesterol efflux 
regulatory protein (Kolovou et al.,2006). ABCA1 is a member of ATP-binding cassette 
transporter family. These integral proteins use ATP as a source of energy to transport variety of 
molecules including ions, vitamins, lipids, peptides proteins and number of hydrophobic 
compounds across intracellular and plasma membranes (Kolovou et al.,2006).  Complete loss of 
ABCA1 function leads to severely decreased cellular cholesterol efflux and cholesterol ester 
accumulation in macrophages and other cells of the reticuloendothelial systems (Rust et 
al.,1999). Due to impaired ability to transport cholesterol out of the peripheral cells, it 
accumulates in body tissues. Therefore clinically, Tangier disease patients present with 
hepatosplenomegaly, enlarged tonsils, neurapathy and most important in our case atherosclerotic 
lesions. Studies suggested that carriers of defective adenosine triphosphate–binding cassette 
transporter A1 bear a moderately increased risk for coronary artery disease.     
Sitosterolemia is a rare autosomal recessive disorder. It characterizes by markedly increased 
intestinal absorption of all sterols including cholesterol, shellfish and plant sterols and impaired 
resecretion of those sterols into bile. Affected individual have expanded body pools of 
cholesterol and very elevated plant-sterol levels. Affected individual will frequently develop 
accelerated atherosclerosis and premature coronary artery disease (Lu et al.,2001) In the studies, 
it has been mapped that this condition results from over 25 mutation in either ABCG5 or ABCG8 
genes which located on chromosome 2 in band 2p21. These genes encode for adenosine 
triphosphate-binding cassette transporter protein (ABC) transporters, steroline-1 and steroline -2. 
Their functions are to limit intestinal absorption and stimulate excretion of noncholesterol sterols 
by liver into bile. Mutation of these transporters predispose to sterol accumulation and early 
artherosclerosis. Sitosterolemia can clinically present similar to homozygous familiar 
hypercholesterolemia in terms of elevated LDL-cholesterol especially in childhood around 300 
mg/dl or 8 mmol/l. Therefore, it a possibility that sitosterolemia is frequently misdiagnosed with 
hyperlipidemia.   
 Although, all mentioned above lipid metabolism disorders are rare, they are high risk 
factors and directly related to incidence of coronary artery disease. Studies of these disorders 
gave researches a better understanding of lipoprotein and cholesterol metabolism. Whether 
hypercholesterolemia is caused by mutation in one gene or cumulative effect of several genes 
defects, early diagnosis is essential to start appropriate therapy. Most notable was development 
of Statins drugs which is a class of medications that was developed to lower plasma low density 




Recently, the first non-lipid related disease causing gene was identified and proposed to be 
responsible for an autosomal dominant form of coronary artery disease (adCAD). However, 
when association is detected, it is still difficult to prove direct causality. False positive 
association may arise due to differences in ethnicity, age or sex [Dzau, 2007]. Several studies 
were performed to identify the role of human myocyte enhancer factor-2A (MEF2A) and its 
mutation in early coronary artery disease development .MEF2A is a protein that is coded by 
MEF2A gene which is located on chromosome 15q26. The seven-amino acid deletion of the 
human transcriptional myocyte enhancer factor-2A was reported to be a functional mutation. It 
disrupted nuclear localization of MEF2A, reduced MEF2A-medieted transcription activation. In 
addition it abolished synergistic activation by MEF2A and by transcriptional factor GATA-
binding protein which involved in cell growth, with which MEF2A interact to regulate the 
expression of the downstream target genes, by dominant –negative mechanism (Wang et 
al.,2003). One study  was dealing with large family with 13 patients who had an autosomal 
dominant patterns of CAD. Nine of 13 patients later developed acute myocardial infarction. 
Further genome wide association study linked data to chromosome 15q26. MEF2A also 
demonstrate its relevance to expression of coronary arteries endothelium (Wang et al.,2003). 
Another independent case-control studies was performed from 2003 to 2007 involving 726 
individuals in China (Han et al.,2007). The results of that study suggested the disease-causing 
relationship between MEF2A and coronary artery disease. In subsequent study, Weng et al who 
report sequencing MEF2A in 300 patients with premature coronary artery disease and control, 
only 1 CAD patient was reported to have the mutation that wasn’t found in the control group 
(Altshuler & Hirschhorn, 2005). Also another study in large Irish population showed no 
association between variation in the MEF2A gene and coronary artery disease (Horan et 
al.,2006).However, the absence of CAD in a control group wasn’t confirmed by angiography. As 
science progresses it is becoming much easier to collect data but it also causes many controversy 
in its analysis. MEF2A plays an important role in cardiovascular biology, but its genetic 
variation contribution to pathophysiology in CAD should be further validated in order to make it 
the criteria for genetic testing for CAD.   
Susceptability genes are those that increase or decrease the risk of developing disease and in 
combination with environmental factors and other genetic factors may contribute to pathogenesis 
of a disease. These genes might have less predictive values for developing a disease, but 
contribute a lot to understanding of pathophysiology process. 
eNOS gene. 
Nitric oxide (NO) is gas and is identified as endothelium derived relaxant factor. NO is 
synthesized from substrate L-arginine  by endothelial cell nitric oxide synthase (eNOS)  which 
encoded by  nitric oxide synthase 3 gene (NOS3) that is located on 26-exon on chromosome 7. 
NO plays a few important roles in healthy endothelium such as regulation of vascular tone in 
coronary arteries, prevents leukocytes adhesion and platelets aggregation and inhibits vascular 
smooth muscle migration and proliferation. Biochemical and/or physical shear stress damages 
endothelium and impairs production of mediator such as nitric oxide. This might lead to 
vasoconstriction, loss of elasticity and promote platelets activation. Indirectly decrease in nitric 
oxide activity affect conditions such as hypertension and hypercholesterolemia which predispose 
to atherosclerosis [Dzau.2007]. Few clinical studies indicated relationship between different 
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eNOS gene polymorphism and atherosclerosis development. The most commonly studied variant 
is Glu298Asp which is conversion of glutamate to aspartate at the position 298 that results from 
G894T substitution within exon 7. In English study sample Glu298T variance has been reported 
to be associated with atherosclerotic coronary arteries. The mechanism is unknown but by 
altering mature protein activity can affect enzyme activity and decreased local nitric oxide 
synthesis. As a result of case-control study involve Iranian population (Salimi et al., 2006), we 
observed that the genotype frequencies differ from allele frequencies significantly between 
control and CAD patients. However, controversy brought up by other small studies that do not 
support these findings. Therefore the relevance of this data remains unclear. It might be because 
of subjects were picked from different ethnicity and genetic background. Further larger studies 
are needed in order to prove major effect of Glu298Asp polymorphism on disease development 
but for now it can be considered as indirect genetic marker associated with the disease. 
TNF-alpha  
Tumor necrosis factor alpha (TNF-alpha) is a pro-inflammatory cytokine that plays a role in 
pathogenesis of CAD. It was localized in atherosclerotic plaque in pathological studies. 
Macrophage derived TNF-alpha has important pro-inflamatory autocrine and paracrine effect. 
Stimulation of the cells by TNF-alpha, activate the cascade of events that lead to upregulation of 
various adhetion molecules. Overall contribution of TNF-alpha believed to be activation of 
influx of additional inflammatory cells and involvement in endothelial dysfunction (Dzau 2007). 
TNF-alpha has two receptors through which it exerts its effect TNFR1 and TNFR2. 
Polymorphisms in TNF-alpha and TNF receptor genes are hypothesized to affect secretion of 
this cytokine and relate to presence or severity of CAD. To investigate this matter scientist 
conducted a study 259 patients with angiographiclly confirmed CAD and control group (Allen et 
al., 2001). As a result of the statistical analysis no significant differences were found between 
polymorphism frequencies. Another European study was performed to investigate association of 
TNF-alpha gene polymorphism and its relationship with CAD via polymerase chain reaction-
single-strand confirmation polymorphism and sequencing (Herrman et al.,1998). Although, 
TNF-alpha gene polymorphism have been associated with number of inflammatory diseases it is 
unlikely to contribute to development of CAD 
Diseased-linked genes are those genes whose expression is linked or connected to the disease but 
the cause and effect relationship is not established. They might serve as biomarkers for the 
disease. A big chunk of genes were newly identified as disease-linked genes for CAD. The most 
studied include intracellular adhesion molecules-2, E-selectine gene, ect. The reason for interest 
in studying disease-linked genes is the fact that about half of the patients who are diagnosed with 
CAD do not have traditionally established risk factors. Therefore, the search for other 
biomarkers was proposed in order to help identify individuals who might be at risk.   
Cellular adhesion molecules. 
 Cell adhesion molecules (CAMs) are transmembrane proteins that involve in binding of cells 
with other cells or extracellular matrix. In healthy endothelium, expression of adhesion 
molecules is very limited. In diseased coronary artery, transendothelial T-cells and monocytes 




 One of 
the CAMs category belong to Immunoglobulin superfamily. They are intracellular adhesion 
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). Animal and human 
studies earlier show that overexpression of adhesion molecules and endothelial cell activation 
causes accumulation of leukocytes in coronary tunica intima. According to latest reports, 
expressions of cellular adhesion molecules is stimulated by cytokins such as interleukin-1, 
tumour necrosis factor (TNF) and interferons-gamma (INF) (Ohta et al., 1999) Furthermore, the 
increased expression of cellular adhesion molecules in atherosclerosis shows in early stages of 
atherosclerotic development which presented by fatty streaks in inner layer of an artery as well 
as the latest fibro-fatty lesions. Linkage of levels of ICAM-1 and VCAM-1 to coronary artery 
disease that was established by study and can be considered as an independent risk predictor 
(Hajilooi et al.,2003).Although, genetic aspect of these molecules remain poorly known, recent  
multi-ethnic study was conducted to investigate relationship of 12/ICAM-1 and 7/VCAM-1 
single nucleotide polymorphism (SNP) and coronary artery calcium and ICAM-1 SNP and 
circulating levels of soluble ICAM-1. It showed no significant association of ICAM-1 and 
VCAM-1 and coronary artery calcium in any ethnic groups, but polymorphism in ICAM-1 
showed significant association with soluble ICAM-1 levels and was identified as a marker for 
atherosclerosis (Bielinski et al ., 2008).   
    Other family of cell adhesion molecules consists of E-selectin and P-selectin. Both of 
them suggested to play an important role in early and advance stages of coronary arthrosclerosis 
from earlier double-knockout mouse experiment.  P-selectine is important in the transient 
attachment of leucocytes to endothelial cells and platelets (Carter et al., 2003). When endothelial 
cells get activated via mediators such as histamine and thrombin in inflammatory process, P-
selectine translocates from internal to endothelial cell surface. Just like prior mentioned cell 
adhesion molecules, P-selectine also contributes to development of atherosclerosis by facilitating 
adhesion of leukocytes to injured endothelium and platelets. Soluble P-selectins were found in 
plasma in multiple conditions including heart disease.   Number of polymorphism has been 
identified in gene encoding P-selectin. THR715Pro polymorphism for example was reported to 
be associated with myocardial infarction in previous studies. In 2003 the study was performed 
that compared levels of soluble P-selectin in 249 individuals with CAD and 252 healthy control 
group and investigated the relationship between polymorphism of  P-selectin and circulated 
soluble P-selectin levels and cardiovascular risk (Carter et al., 2003). It showed that levels of 
soluble P-selectin were higher in affected individuals than control group after adjustment for age 
sex and smoking status. Moreover, no significant association was found between P-selectin 
polymorphism in CAD affected patients and healthy control group. This study suggested that the 
relationship between Thr715Pro polymorphism and levels of soluble P-selectins exist but its 
mechanism is still unclear. 
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   E-selectin also involved in adhesion of leukocytes to activated  endothelium. Mutation 
of E-selectin gene, due to G to T mutation (G98T) in untranslated region of exon 2, was found to 
be significantly higher in frequency in patients with CAD than control group and thus suggests 
association with premature coronary artery disease (Zheng et al.,2001).Even after adjustment for 
other multifactor, mutation of G98T may be an independent risk factor for premature CAD. 
Another study was performed in 2006 within Saudi Arab population. It attempted to investigate 
amino acid change from serine to arginine at codon 128 (S128R), which corresponds toA>C 
nucleotide change at the position 561 (A561C), in the epidermal growth factor-like domain of 
the E-selectin gene that was previously implicated in pathogenesis of CAD in few ethnic groups 
(Abu-Amero et al., 2006). The frequency of mutation in 128r allele was found to be much higher 
in patients with CAD than control group, but lost association with adjustment for other CAD risk 
factors. The most recent study that investigated Association of E-selectin gene (S128R) 
polymorphism in patients with CAD within Indian population was consisted with previous 
findings. It revealed the increased frequency of E-selectin polymorphism in CAD patients but its 
interaction with other risk factors showed that in fact the significant determinant of coronary 
artery disease were presents of diabetes, hypertension, smoking habit, elevated serum 
triglycerides and low HDL level.  
The involvement of cell adhesion molecules was established to play an important role in 
development of atherosclerosis. Overall studies suggest that neither the measurements of soluble 
adhesion molecules, nor screening for their gene polymorphisms cannot be an independent 
predictor of CAD. It may only offer some additional marker of atherosclerosis but cannot go 
beyond the assessment of conventional coronary artery disease risk factors. 
Conclusion:  
Throughout last decade significant advances in genetic studies were made which gave us a fair 
insight on pathogenesis of coronary artery disease. It no longer viewed as a simply degenerative 
disease or gradually accumulating lipid disease. Current views regard CAD as complex disease 
that involved in active process of alteration in cell intercommunication and cell signaling. At this 
point in time we can only speculate on assumed biological role of genetic polymorphisms that 
has been identified in relationship with CAD. Field in genetic studies is promising and expects to 
accelerate as future studies will focus on identifying new genetic polymorphism in connection to 
CAD. However, at this time coronary artery disease can’t be simply diagnosed through genetic 
testing, but can only look for variants that increase the risk of developing it. Prediction of CAD 
via genetic polymorphism may eventually lead to clinical utilization, but now only physician can 
diagnose the disease based on a medical history, family history, risk factors and the results of 
medical tests. Genetic testing can not clearly tell if disease is going to develop or not, but if 
certain genetic markers are present, it may help us to modify our estimated risk of developing it. 
When considered genetics along with other individual’s information including other risk factors 
may help individual to reduce the risks that we can control such as lifestyle, diet and exercise. 
Moreover, if clinician knows about increased genetic predispositions, they may stronger 
recommend lifestyle changes. In addition, high index of suspicion might result in early 
diagnostic application and close monitoring of patient with marked genetic polymorphism by 
their doctors.  Currently a few of screening tests are available for asymptomatic individuals who 
are at risk for premature atherosclerosis and CAD such as computed tomography, ultrasound ect. 
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Hopefully in near future genetic studies will lead us to revolutionary changes in further 
understanding, ability to diagnose, prevent and treat the wold’s biggest killer.  
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